Drug Trial Radar · NCT07525206
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
990
Planned (sponsor's estimate)
Start
May 22, 2026
Primary completion
May 2029
Study completion Mar 2030
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Apr 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. The purpose of this study is to assess the adverse events and change in disease activity of telisotuzumab adizutecan plus bevacizumab compared to standard of care (SOC) of LONSURF (trifluridine and tipiracil) plus bevacizumab in adult participants with refractory metastatic colorectal cancer (mCRC). Telisotuzumab adizutecan is an investigational drug being developed for the treatment of CRC. Participants will then be randomized into 2 groups called treatment arms. One group will receive telisotuzumab adizutecan with bevacizumab in different doses. Another group will receive standard of care (SOC), trifluridine and tipiracil (LONSURF), with Bevacizumab. Up to approximately 990 adult participants with refractory mCRC, will be enrolled in the study in approximately 125 sites globally. In this Phase 3, one of two groups will receive doses of Intravenous (IV) telisotuzumab adizutecan + bevacizumab and other group will receive oral SOC of trifluridine/tipiracil (LONSURF)+ Intravenous (IV) bevacizumab. The study will run for a duration of approximately of 36 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Conditions
- Colorectal Cancer
Interventions
Telisotuzumab adizutecanDrug
Intravenous (IV)
BevacizumabDrug
Intravenous (IV)
Trifluridine/TipiracilDrug
Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 3: Objective Response (OR) as assessed by Blinded Independent Central Review (BICR)Time frame: Up to Approximately 15 Months
- Phase 3: Overall Survival (OS)Time frame: Up to Approximately 36 Months
Locations
91 sites in 11 countries. Site status is shown where the registry gives one.
City Of Hope - Phoenix /ID# 279450
Goodyear, Arizona · Recruiting
Highlands Oncology Group - Springdale /ID# 279444
Springdale, Arkansas · Recruiting
City of Hope National Medical Center /ID# 279449
Duarte, California · Recruiting
Rocky Mountain Cancer Centers - Aurora /ID# 280112
Aurora, Colorado · Recruiting
Yale University School of Medicine /ID# 279373
New Haven, Connecticut · Recruiting
Moffitt Cancer Center /ID# 279325
Tampa, Florida · Recruiting
City Of Hope - Atlanta /ID# 280017
Newnan, Georgia · Recruiting
University of Chicago Medical Center /ID# 279365
Chicago, Illinois · Recruiting
Saint Lukes Hospital of Kansas City /ID# 279513
Kansas City, Missouri · Recruiting
Astera Cancer Care /ID# 279532
East Brunswick, New Jersey · Recruiting
Northwell Health Center for Advanced Medicine. /ID# 279590
Lake Success, New York · Recruiting
Duke University Medical Center /ID# 279322
Durham, North Carolina · Recruiting
Oncology Hematology Care - Blue Ash /ID# 280143
Cincinnati, Ohio · Recruiting
Compass Oncology - Rose Quarter /ID# 280127
Portland, Oregon · Recruiting
Texas Oncology - Abilene - Antilley Road /ID# 280120
Abilene, Texas · Recruiting
The University of Texas MD Anderson Cancer Center /ID# 279865
Houston, Texas · Recruiting
Blue Ridge Cancer Care - Blacksburg /ID# 280115
Blacksburg, Virginia · Recruiting
Fred Hutch Cancer Center /ID# 281451
Seattle, Washington · Recruiting
Imelda Ziekenhuis /ID# 279333
Bonheiden, Antwerpen, Belgium · Recruiting
Universitair Ziekenhuis Antwerpen /ID# 279334
Edegem, Antwerpen, Belgium · Recruiting
Institut Jules Bordet /ID# 279406
Anderlecht, Brussels Capital, Belgium · Recruiting
Cliniques Universitaires UCL Saint-Luc /ID# 279335
Brussels, Brussels Capital, Belgium · Recruiting
Universitair Ziekenhuis Brussel /ID# 279535
Jette, Brussels Capital, Belgium · Recruiting
Grand Hopital de Charleroi - Les Viviers /ID# 279336
Charleroi, Hainaut, Belgium · Recruiting
Universite Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant /ID# 280014
Yvoir, Namur, Belgium · Recruiting
AZ Maria Middelares /ID# 280141
Ghent, Oost-Vlaanderen, Belgium · Recruiting
Universitair Ziekenhuis Leuven /ID# 279330
Leuven, Vlaams-Brabant, Belgium · Recruiting
AZ-Delta. /ID# 279329
Roeselare, West-Vlaanderen, Belgium · Recruiting
Centro Gaucho Integrado De Oncologia, Hematologia, Ensino E Pesquisa /ID# 279572
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto /ID# 279574
São José do Rio Preto, São Paulo, Brazil · Recruiting
Beijing Hospital No. 2 /ID# 279666
Beijing, Beijing Municipality, China · Recruiting
Beijing Friendship Hospital /ID# 279766
Beijing, Beijing Municipality, China · Recruiting
Sun Yat-Sen University Cancer Center /ID# 279670
Guangzhou, Guangdong, China · Recruiting
Zhujiang Hospital /ID# 279667
Guangzhou, Guangdong, China · Recruiting
Guangxi Medical University Cancer Hospital /ID# 279707
Nanning, Guangxi, China · Recruiting
Harbin Medical University Cancer Hospital /ID# 279961
Harbin, Heilongjiang, China · Recruiting
Henan Cancer Hospital /ID# 279678
Zhengzhou, Henan, China · Recruiting
Union Hospital - Tongji Medical College /ID# 283649
Wuhan, Hubei, China · Recruiting
Hubei Cancer Hospital /ID# 279687
Wuhan, Hubei, China · Recruiting
Affiliated Hospital Of Jiangnan University(Wuxi Fourth People'S Hospital ) /ID# 280200
Wuxi, Jiangsu, China · Recruiting
Showing 40 of 91 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.